Indonesia Plans to Produce 462 Million Doses of Covid-19 Vaccines in 2022

Indonesia plans to produce 462 million doses of the Covid-19 coronavirus vaccine in 2022. This amount is estimated to be sufficient to meet the needs of both government and private vaccination programs.

The largest production of the coronavirus vaccine is planned by Bio Farma using Sinovac bulk, namely 138 million doses. Production of the Merah Putih vaccine, produced by Universitas Airlangga and Biotis, is estimated to reach 120 million doses.

There is also production of a state-owned enterprise (BUMN) vaccine produced by Bio Farma in collaboration with Baylor College of Medicine, reaching 77 million doses. Kalbe Farma will process 55 million doses of the Sinopharm vaccine.

Production of the JBio-Zifivax vaccine is estimated to reach 50 million doses. Meanwhile, production of the Etana-Yuxi Walvax Biotech and Kalbe Farma-Genexine vaccines will be 12 million doses and 10 million doses respectively.

It is estimated that 12 million doses of the coronavirus vaccine will begin production in January 2022. This will increase to 17 million doses per month from February to May 2022.

A total of 29 million doses of the coronavirus vaccine will be produced domestically in June 2022. This figure will increase to 51 million doses in July 2022. Then, the production of the coronavirus vaccine in Indonesia will increase to 61 million doses per month from August to December 2022.

Vaccination is important to reduce the risk of illness and death from the virus. Therefore, the public is urged to participate in the ongoing vaccination program.

In addition, the public is urged to diligently implement the 3M health protocols: wearing masks, maintaining distance, and washing hands with soap. These health protocols can prevent the spread of the coronavirus.